BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C, page-6

Would you like me to pick those results to bits like I have done ten times already.

G3
Standard Int/Rib course = 6 months.

And very successful overall with INT/Rib.

Why was this 12?

Why did the figures mentioned not say that the 68.8% included failures BUT Biotron's trial results did not?

Why did they word the results to make it appear that 225 was responsible for the CURE; when, in fact (with the doubling of the time for standard of care) it was the Standard treatment that produced a standard result.

There were no breakthroughs........ and there should not have been.

SVR failure was 3/8 if you count the trial to the same standard as Biotron report for standard overall in Thailand.




I could go on but you know all this already. Unfortunately, you are a Biotron tragic and don't mind newbies getting the wrong idea. Years of ramping won't change what pharma know, it's them you need to convince not the sheeple on here.